TGA Peptide Rules in Australia (2026)

The short answer

In Australia, peptides are regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989. Many research peptides are not approved medicines and are not listed on the Australian Register of Therapeutic Goods (ARTG). Several peptides are also captured by the Poisons Standard as Schedule 4 (Prescription Only Medicine) substances, and at least one, BPC-157, was added by name to Schedule 4 and Appendix D with effect from 1 June 2024.

For a research-use-only supplier such as NovaPeptides, the practical point is simple. These materials are supplied for laboratory and research purposes only. They are not approved medicines, not for human or animal use, and not marketed with any therapeutic claims. The sections below explain the framework in plain terms.

How the TGA and the Poisons Standard work

The TGA administers the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). The Poisons Standard places substances into Schedules, and the controls become more restrictive as the Schedule number rises. The Schedules are then given legal force by state and territory legislation.

The Schedules most relevant to medicines

• Schedule 2 (Pharmacy Medicine): available from a pharmacy, with pharmacist advice where needed.
• Schedule 3 (Pharmacist Only Medicine): supplied by a pharmacist without a prescription, but with professional advice.
• Schedule 4 (Prescription Only Medicine): requires a prescription from an authorised prescriber.
• Schedule 8 (Controlled Drug): tighter possession, record-keeping and supply controls.
• Schedule 9 (Prohibited Substance): substances generally available only for approved research or analytical purposes.

Appendix D sits alongside the Schedules. It lists additional controls on the possession or supply of certain Schedule 4 or Schedule 8 poisons. An Appendix D entry signals that a substance carries extra restrictions beyond a standard prescription-only classification.

Scheduling of peptides: Schedule 4 and Appendix D

A number of peptides fall within Schedule 4 of the Poisons Standard, meaning they are treated as prescription-only substances. The clearest worked example is BPC-157. According to TGA scheduling records, BPC-157 was added to Schedule 4 and to Appendix D with effect from 1 June 2024.

This is notable because Australia was among the first jurisdictions to schedule BPC-157 by name rather than relying only on broad definitions. Before that decision, BPC-157 was unscheduled in the Poisons Standard. The TGA has published its reasons through the normal scheduling consultation process, which involves public notices of interim and final decisions.

The broader message for 2026 is that scheduling is dynamic. A substance that is unscheduled today can be scheduled later as the TGA reviews referrals, safety information and importation activity. Anyone working with research peptides should treat the current Poisons Standard as the source of truth rather than assuming a fixed status.

The ARTG and what not approved means

The Australian Register of Therapeutic Goods (ARTG) is the public register of therapeutic goods that the TGA has assessed and permitted for supply in Australia. Products on the ARTG have been evaluated for quality, safety and, where relevant, efficacy for their approved purpose.

Most research peptides are not on the ARTG. In regulatory language they are unapproved therapeutic goods, which means they have not been evaluated or approved by the TGA for therapeutic use. Being absent from the ARTG does not, by itself, make a substance a research chemical. It simply means the TGA has not assessed it as a medicine, so no therapeutic claims can lawfully be made about it.

Research compound versus approved medicine

There is a meaningful difference between a research-use-only compound and an approved medicine. An approved medicine has an ARTG entry, an assessed manufacturing standard, approved labelling and a defined therapeutic indication. A research-use-only compound has none of these. It is a laboratory material supplied for research purposes, not for diagnosis, treatment or prevention of any condition.

Research-use-only positioning is a compliance boundary, not a marketing slogan. It means the material is not presented for human or animal consumption, is not accompanied by dosing guidance, and is not described with therapeutic or performance benefits. Keeping that boundary clear is central to lawful supply of unapproved substances.

Typical distinctions

• Approved medicine: ARTG listed, therapeutic indication, prescriber or pharmacy pathway.
• Research-use-only compound: not ARTG listed, no therapeutic claims, laboratory use only.
• Scheduled research peptide: may also be Schedule 4 or Appendix D, adding possession and supply controls.

Importation and supply rules

The TGA has publicly set out responsibilities for importing, compounding and supplying unapproved peptide products, and has flagged unapproved peptides as a compliance focus area. The TGA has also warned about the risks of importing unapproved peptide products and has noted that poorly labelled products may not be considered for release under the Personal Importation Scheme.

The Personal Importation Scheme is a narrow pathway, and the TGA has stated that it does not permit practitioners or clinics to import unapproved goods for stock or for supply to patients. Compounding is similarly limited. Extemporaneous preparation is generally tied to a valid prescription for a specific individual where no suitable approved alternative exists. These settings are complex, which is one reason this guide points readers to the TGA directly rather than offering interpretation.

Sport and anti-doping

Separate from the TGA, anti-doping rules apply to athletes. Sport Integrity Australia administers the World Anti-Doping Code in Australia. Many research peptides, including BPC-157, are captured by the World Anti-Doping Agency (WADA) Prohibited List under category S0, Non-Approved Substances, which covers substances not approved for human therapeutic use by any government health authority.

S0 substances are prohibited at all times in sport. Athletes and support personnel subject to anti-doping rules should treat non-approved peptides as high risk and consult Sport Integrity Australia for current status before using any substance.

What this means for 2026 and staying compliant

As at the time of writing, the 2026 landscape can be summarised as follows. Peptides remain therapeutic goods under the Act. Many are unapproved and absent from the ARTG. Some, including BPC-157, are scheduled substances with added controls. The TGA continues to treat unapproved peptide products as a compliance priority, and anti-doping prohibitions apply independently in sport.

For NovaPeptides, compliance means staying inside a research-use-only frame. That means supplying materials for laboratory and research purposes only, making no therapeutic, performance or weight-related claims, publishing no human dosing or protocols, and directing anyone with regulatory questions to the TGA and other official sources. This article reflects that positioning and is intended as neutral background, not a recommendation to use any substance.

Research-use-only is a boundary we hold, not a disclaimer we hide behind. No human use, no claims, no protocols.

Frequently asked questions